GlassScriptPhysician profile
Benjamin Daniel Roberts
NPI 1922653039
$7,509.60
in general payments reported to CMS, 2019-2025
48 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,498 · 2022: $1,442 · 2023: $1,482 · 2024: $1,790 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,252.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.53 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Astrazeneca Pharmaceuticals LP | $424.46 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $422.56 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Supernus Pharmaceuticals, INC. | $409.37 | 2022-2024 | Qelbree, Xyosted, Qelbree |
| Novo Nordisk INC | $316.29 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Indivior INC. | $297.76 | 2021-2025 | Sublocade |
| Alkermes, INC. | $251.95 | 2021-2025 | Aristada, Lybalvi |
| Bayer Healthcare Pharmaceuticals INC. | $206.42 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.21 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $191.18 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $189.67 | 2021-2024 | Yupelri |
| Neurocrine Biosciences, INC. | $163.36 | 2022-2023 | Ingrezza |
| Antares Pharma, INC. | $161.81 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Pfizer INC. | $156.51 | 2022-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $149.17 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $120.26 | 2021-2025 | Verquvo, Vaxneuvance, Gardasil 9 |
| Dexcom, INC. | $106.19 | 2021-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $94.36 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $86.67 | 2021-2023 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $69.42 | 2021-2022 | |
| Braeburn INC. | $57.62 | 2023-2025 | Brixadi |
| Organon LLC | $56.21 | 2021-2024 | Nexplanon |
| Axsome Therapeutics, INC. | $55.29 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $55.22 | 2024 | Fanapt |
| Halozyme INC | $52.97 | 2023 | |
| Medtronic, INC. | $51.84 | 2023-2024 | Intellis Adaptivestim, Minimed 770g |
| Eisai INC. | $47.26 | 2021-2022 | |
| Amgen INC. | $45.37 | 2021-2025 | Repatha, Otezla |
| Lundbeck LLC | $40.63 | 2024 | Rexulti |
| Corium, LLC | $31.26 | 2025 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $30.55 | 2021 | |
| Seqirus USA INC | $24.75 | 2025 | Flucelvax |
| Tris Pharma INC | $21.83 | 2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $21.75 | 2023 | |
| Biogen, INC. | $21.43 | 2022 | |
| Viatris Specialty LLC | $20.60 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $19.18 | 2021 | |
| Baxter Healthcare | $18.45 | 2025 | Hillrom - Volara System |
| Cranial Technologies, INC | $18.31 | 2022 | |
| Inspire Medical Systems, INC. | $18.17 | 2024 | Inspire |
| Boston Scientific Corporation | $15.90 | 2023 | Wavewriter Alpha Prime 16 |
| Jazz Pharmaceuticals INC. | $14.50 | 2021 | |
| Redhill Biopharma INC. | $14.45 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.86 | 2022 | |
| Sumitomo Pharma America, INC. | $11.45 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.